Janus Henderson Group PLC Mersana Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $34 - $129	33 Added 0.11%	30,649 $38,000
Q2 2023 Aug 14, 2023	SELL	$3.08 - $9.55 $123 - $382	-40 Reduced 0.13%	30,616 $100,000
Q1 2023 May 15, 2023	BUY	$4.0 - $7.02 $77,260 - $135,591	19,315 Added 170.31%	30,656 $125,000
Q4 2022 Feb 14, 2023	SELL	$5.65 - $7.86 $5 - $7	-1 Reduced 0.01%	11,341 $66,000
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $4 - $8	-1 Reduced 0.01%	11,342 $77,000
Q2 2022 Aug 15, 2022	BUY	$2.84 - $5.0 $411 - $725	145 Added 1.29%	11,343 $53,000
Q1 2022 May 16, 2022	SELL	$3.74 - $6.63 $33 - $59	-9 Reduced 0.08%	11,198 $45,000
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $61,414 - $110,501	11,207 New	11,207 $70,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $14.1 Million - $24.4 Million	-919,101 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $172,711 - $282,963	10,256 Added 1.13%	919,101 $24.5 Million
Q3 2020 Nov 16, 2020	BUY	$16.2 - $25.7 $13.8 Million - $21.9 Million	851,478 Added 1484.26%	908,845 $16.9 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $300,603 - $1.34 Million	57,367 New	57,367 $1.34 Million

121

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $198M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.